Sutro BiopharmaSTRO
About: Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Employees: 310
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
263% more call options, than puts
Call options by funds: $243K | Put options by funds: $67K
11% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 36
1.0% more ownership
Funds ownership: 76.28% [Q3] → 77.28% (+1.0%) [Q4]
6% less funds holding
Funds holding: 130 [Q3] → 122 (-8) [Q4]
20% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 30
46% less capital invested
Capital invested by funds: $216M [Q3] → $117M (-$99.1M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Andrew Fein 31% 1-year accuracy 109 / 353 met price target | 122%upside $2 | Neutral Downgraded | 17 Mar 2025 |
Wedbush David Nierengarten 39% 1-year accuracy 45 / 115 met price target | 122%upside $2 | Neutral Downgraded | 14 Mar 2025 |
B of A Securities Tazeen Ahmad 25% 1-year accuracy 8 / 32 met price target | 11%upside $1 | Underperform Downgraded | 14 Mar 2025 |
Financial journalist opinion









